matrix hormones semaglutide Proteomic changes upon treatment with in individuals with obesity Phase 3 Trial of Semaglutide

space dose increases gradually over 1216 weeks rather than rapid escalation

Shed Best for Dosing Format Flexibility OVERALL SCORE Good Based on our comprehensive hands-on evaluation Payments HSA / FSA eligible

weight loss (Phase 2/3 peak) | ~15% | ~22% | ~24% | | FDA Status | Approved (Wegovy, Ozempic) | Approved (Zepbound, Mounjaro) | Phase 3 (2026) | | Dosing frequency | Weekly | Weekly | Weekly | The additional glucagon receptor agonism is believed to be responsible for retatrutide's greater metabolic rate increase and enhanced fat oxidation compared to dual agonists

N-acetylcysteine (NAC) or N- Acetyl-L- Cysteine or Mucomyst is an analog of the amino acid cysteine